Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.78
+0.25007.08%
Post-market: 3.72-0.0600-1.59%19:46 EDT
Volume:2.20M
Turnover:8.24M
Market Cap:414.95M
PE:-22.24
High:3.81
Open:3.54
Low:3.54
Close:3.53
52wk High:5.45
52wk Low:2.53
Shares:109.77M
Float Shares:84.96M
Volume Ratio:2.00
T/O Rate:2.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:1.13
PE(LYR):-1.88

Loading ...

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 04

Rocket Pharmaceuticals Inc Expected to Post Earnings of 37 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Rocket Pharmaceuticals - Rp-A501 Well-Tolerated in Initial Three Patients with no Tma or Capillary Leak Syndrome

THOMSON REUTERS
·
Aug 03

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease

THOMSON REUTERS
·
Aug 03

Rocket Pharmaceuticals - Engaging with FDA on Pivotal Trial; Regulatory Update Expected in H2 2026

THOMSON REUTERS
·
Aug 03

Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle

Reuters
·
Aug 01

Rocket Pharmaceuticals Principal Accounting Officer Joseph Manhede Files Initial Beneficial Ownership Statement

Reuters
·
Jul 09

Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8

Reuters
·
Jul 01

Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million

Reuters
·
Jun 12

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

THOMSON REUTERS
·
Jun 12

Bank of America Securities Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Jun 11

Rocket Pharmaceuticals price target raised to $10 from $9 at BofA

TIPRANKS
·
Jun 03

Bank of America Securities Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Jun 03

Rocket Pharma to present at Jefferies Global Healthcare Conference

Reuters
·
May 28

Rocket Pharma CEO Gaurav Shah sells 55,684 shares for $171,787.82

Reuters
·
May 27

Rocket Pharmaceuticals shareholders approve stock option exchange program at annual meeting

Reuters
·
May 21

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 11

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
May 11

Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says

MT Newswires Live
·
May 09

Wedbush Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
May 08